The US Food and Drug Administration gave the SGLT2 inhibitor empagliflozin (Jardiance) a new indication for treating adults with isolated chronic kidney disease.
Study findings suggest that patients be screened for vitamin D deficiency before starting SGLT2 inhibitor therapy, or they should simply be prescribed vitamin D supplements.
However, an important take-home message from this new meta-analysis is that these widely used medications appeared to be safe even in acutely ill hospitalized patients, the researchers say.
Results of the DICTATE-AHF randomized trial that tested starting dapagliflozin for patients hospitalized with acute heart failure confirmed the safety and benefit of this guideline-directed strategy.